ProPhase Labs (NASDAQ:PRPH) Stock Price Passes Below 200 Day Moving Average of $4.47

ProPhase Labs, Inc. (NASDAQ:PRPH)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.47 and traded as low as $2.48. ProPhase Labs shares last traded at $2.53, with a volume of 14,002 shares traded.

Analyst Ratings Changes

Separately, StockNews.com raised shares of ProPhase Labs to a “sell” rating in a research note on Wednesday, June 26th.

ProPhase Labs Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.58 and a quick ratio of 1.44. The firm has a market capitalization of $48.27 million, a P/E ratio of -2.34 and a beta of -0.10. The firm’s 50 day simple moving average is $3.04 and its two-hundred day simple moving average is $4.47.

Hedge Funds Weigh In On ProPhase Labs

An institutional investor recently raised its position in ProPhase Labs stock. Vanguard Group Inc. increased its stake in ProPhase Labs, Inc. (NASDAQ:PRPH) by 1.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 618,763 shares of the company’s stock after buying an additional 9,416 shares during the period. Vanguard Group Inc. owned 3.43% of ProPhase Labs worth $4,003,000 at the end of the most recent reporting period. Institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.